Taking the "Cryptogenic" Out of Cryptogenic Stroke

Slides:



Advertisements
Similar presentations
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Advertisements

R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
CHA2DS2-VASc Scoring System General AF Treatment Guidance.
Silent No More:.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Monitoring Continuum ISSUE-3 Atrial Fibrillation Classification.
Preventing Thrombotic Complications in ACS: State of the Art
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
Appropriate Stroke Prevention Strategies in Atrial Fibrillation
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Oral Anticoagulants in AFa,b A Brief History.
Selecting NOACs for High-Risk Patients
A Case Challenge: Anticoagulant Choices for Acute PE
A Call to Action on Cryptogenic Stroke
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
Heart Failure Prevention: Mission Impossible?
How to Adjust Anticoagulant Dosing
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
What Anticoagulant Registries Are Revealing
VTE in Cancer.
Oral Anticoagulation in AF
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
NOACs in AF: Consequences of Underdosing and NonAdherence
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Imaging to Assess IPF Progression A Case-Based Approach
NOAC Studies in VTE AF Studies Superior Outcomes.
Iron Deficiency in Heart Failure
Hypoglycemia Is BAD.
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in AF: Consequences of Underdosing and NonAdherence
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
Taking the "Cryptogenic" Out of Cryptogenic Stroke
5 Good Minutes on Atrial Fibrillation-related Stroke
What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
How to Adjust Anticoagulant Dosing
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Program Goals

Patient Case: Presentation

Time Is Brain: Neurologic Exam

Stroke Etiologies

Cryptogenic vs ESUS

ESC Recommendations for Screening for AF

Arrhythmia Monitoring

The More You Look, The More You Find How AF Is Detected in Patients With CS

CRYSTAL AF: Trial Design

CRYSTAL AF Detection of AF by 36 Months

Why Is Finding AF Important in a Patient With Cryptogenic Stroke?

Diagnosis of AF by ECG

Importance of Assessing Source of Stroke

Prevention of ESUS NOAC vs ASA Ongoing Trials

Teamwork Approach

All-Cause Mortality in AF Impact of Baseline Characteristics

Use of Anticoagulants in Ischemic Stroke

Hospital Discharge Following a Stroke

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.